Replies to post #95632 on Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

"they added another Study to increase LymPro's Value" ???

whose they ??? are you talking about the FY05 P-1 studies where the question raised is "Does LymPro Work" - also, do we not know whether or not BD (or maybe even Quest or/=) is requiring these additional test results before moving the ball further down court?

http://finance.yahoo.com/news/meeting-amarantus-confirms-fundamental-turnaround-160000478.html

Amarantus tells us they are now in the process of going back and doing a 7-year follow-up analysis of the 88 patients studied in the Phase 1 trial above. This will be an incredibly important longitudinal analysis for the validation of LymPro. Investors need to understand, the “Gold Standard” for Alzheimer’s disease diagnosis is an autopsy. Obviously this limits data validation while the patient is still alive. Therefore, data from the Phase 1 study was compared to the physician’s diagnosis. The 88 patient Phase 1 study was conducted in subjects with mild-to-moderate dementia previously diagnosed as having probably AD (n=32) or dementia with PD (n=26), vs. a healthy control (n=30). In-between the initial physician’s diagnosis and autopsy (patient death) are follow-up examinations. LymPro compared well to the physician’s initial diagnosis. However, actual real-world follow-up data from the 58 subjects diagnosed with AD or PDD will give a definitive answer to the question, “Does LymPro work?”

could the new P-1 additional test layering results be yet another reason why a JV Agreement has turned into "were going it alone" - in addition to the CPT billing code conference news - which also brought us to "were going it alone" - if so, then we'll need to dissect this much deeper...